Yahoo · Nov 4, 2026
Eli Lilly Stocks Rise 2.32% While Revenue Guidance Faces a Quality-of-Growth Test
The latest quarter includes benefits that should be separated from underlying demand.
NASDAQ · LLY
Eli Lilly and Company
Healthcare · Drug Manufacturers - General
$1,417.99
Up+$8.34 (+0.59%)
Updated Nov 5, 2026, 6:18 AM
SID Score
7.0/10
Composite research score
Smart Money
44/100
Neutral
- Market cap
- 906.5B
- P/E ratio
- 49.16
- Dividend yield
- 0.55%
- 52-week range
- $850.51 – $1,449.68
- Volume
- 3.64M
- Avg. volume
- 3.8M
Price performance · LLY
LLY price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
LLY closed at $1,417.99 after 21 trading sessions, up 19.29% for the selected period.
- Last close
- $1,417.99
- Period change
- +19.29%
- Period low
- $1,166.51
- Period high
- $1,417.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $1,440.00 | $1,445.96 | $1,401.59 | $1,417.99 | 3.64M |
| Nov 3, 2026 | $1,399.63 | $1,437.00 | $1,393.47 | $1,409.38 | 2.84M |
| Nov 2, 2026 | $1,393.15 | $1,421.99 | $1,382.02 | $1,410.99 | 3.74M |
| Oct 30, 2026 | $1,428.83 | $1,449.68 | $1,408.36 | $1,417.54 | 5.25M |
| Oct 29, 2026 | $1,332.73 | $1,408.38 | $1,330.00 | $1,373.70 | 4.37M |
| Oct 28, 2026 | $1,268.55 | $1,299.43 | $1,260.34 | $1,288.30 | 2.06M |
| Oct 27, 2026 | $1,273.50 | $1,297.92 | $1,272.0703 | $1,281.91 | 1.85M |
| Oct 26, 2026 | $1,286.39 | $1,296.90 | $1,273.7293 | $1,279.14 | 2.11M |
| Oct 23, 2026 | $1,304.15 | $1,307.9199 | $1,257.62 | $1,273.46 | 2.28M |
| Oct 22, 2026 | $1,281.76 | $1,321.21 | $1,275.10 | $1,306.69 | 2.66M |
| Oct 21, 2026 | $1,266.905 | $1,279.28 | $1,261.08 | $1,270.75 | 1.88M |
| Oct 20, 2026 | $1,263.50 | $1,311.75 | $1,260.17 | $1,283.66 | 2.97M |
| Oct 19, 2026 | $1,243.39 | $1,259.75 | $1,239.10 | $1,240.34 | 1.96M |
| Oct 16, 2026 | $1,256.00 | $1,274.56 | $1,251.25 | $1,257.03 | 2.41M |
| Oct 15, 2026 | $1,235.04 | $1,275.88 | $1,230.66 | $1,251.61 | 3.76M |
| Oct 14, 2026 | $1,177.87 | $1,216.714 | $1,174.24 | $1,208.74 | 3.17M |
| Oct 13, 2026 | $1,190.70 | $1,193.30 | $1,158.405 | $1,166.51 | 1.84M |
| Oct 12, 2026 | $1,181.24 | $1,188.70 | $1,172.805 | $1,182.62 | 1.25M |
| Oct 9, 2026 | $1,153.56 | $1,179.82 | $1,151.67 | $1,179.27 | 1.39M |
| Oct 8, 2026 | $1,183.50 | $1,186.0903 | $1,131.21 | $1,169.60 | 3.09M |
| Oct 7, 2026 | $1,173.62 | $1,206.63 | $1,166.00 | $1,188.72 | 2.31M |
Latest LLY news
The latest Smart Investors Daily articles mentioning LLY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LLY research
Overview
Company profile and research snapshot.
Company profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $1,055.92
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 30, 2026 | RBC Capital | Outperform | — |
| Oct 30, 2026 | Truist Securities | Buy | — |
| Oct 30, 2026 | Wells Fargo | Overweight | — |
| Oct 30, 2026 | Morgan Stanley | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 4, 2026
Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone
Novo Nordisk shares surged Wednesday on a single metric from the Wegovy earnings call that suggested the oral pill is reshaping the obesity market faster than Wall Street expected, even as prices fall and a rival closes in.
Yahoo · Nov 4, 2026
CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index
Sanofi ranked first in the 2026 CNS Summit Digital Innovation Index, developed in collaboration with IDEA Pharma, a division of SAI MedPartners, placing in the top three in all three categories. The rankings were revealed today on the CNS Summit 2026 main stage at Encore Boston Harbor.
Yahoo · Nov 4, 2026
Novo’s Comeback Gets a Pill-Shaped Boost as Wegovy Starts to Bite Back
Novo Nordisk finally has some momentum again. Its Wegovy pill is selling faster than expected, lifting the company’s outlook and giving the Danish drugmaker a credible route back into an obesity market that Eli Lilly has spent the past two years making its own.
AI research layers
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company Stock Performance
Eli Lilly and Company shares closed at $1,409.38, reflecting a single-session decline of 1.66% per SID market data. Despite the pullback, LLY has delivered robust returns across multiple timeframes, gaining 23.46% over the past month, 26.47% over three months, and 27.34% over the trailing twelve months. The stock trades substantially above key moving averages, with the current price sitting 17.4% above the 50-day moving average of $1,200.25 and 29.3% above the 200-day moving average of $1,090.20, according to SID market data. The 14-day relative strength index registers at 81.9, placing LLY firmly in overbought territory. The company's beta of 0.369 indicates significantly lower volatility than the broader market. Eli Lilly commands a market capitalization of approximately $906.5 billion, with average daily trading volume of roughly 3.8 million shares, underscoring deep liquidity for institutional participants.
Eli Lilly and Company Valuation Analysis
Eli Lilly trades at a price-to-earnings ratio of 49.16, a significant premium relative to the broader Healthcare sector, reflecting the market's pricing of elevated future growth expectations, per SID market data. The PEG ratio stands at 1.47, suggesting that while the earnings multiple is high, projected earnings growth partially justifies the premium valuation. The company's price-to-book ratio registers at 38.04, according to SEC filings, indicating that investors are paying a substantial markup over the firm's reported book value, consistent with an asset-light pharmaceutical business model driven by intellectual property. Eli Lilly offers a dividend yield of approximately 0.59%, modest by Healthcare sector standards but reflective of the company's prioritization of reinvestment in research and development pipelines. The valuation profile positions LLY as a high-growth healthcare name rather than a traditional income or value play, with premium multiples across all standard metrics.
Smart Money Activity for LLY
Eli Lilly's composite smart money score stands at 44 out of 100 with a neutral signal, according to SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating strong conviction from large asset managers and pension funds. Insider activity scores a moderate 7.1 out of 25, with SEC Form 4 filings revealing 13 insider transactions over the past 90 days, comprising 8 purchases and 5 sales. The net buying bias among insiders suggests measured confidence from corporate officers and directors, though the overall score remains middling. Dark pool activity registers at 9.1 out of 25, reflecting below-average off-exchange accumulation activity per SID market data. Congressional trading interest scores just 3.2 out of 25, indicating minimal disclosed trading activity among members of Congress. The divergence between maximum institutional conviction and subdued scores in other categories produces the overall neutral composite reading, suggesting institutional holders remain firmly positioned while other smart money cohorts show limited incremental activity.
Eli Lilly and Company Earnings Outlook
Eli Lilly has delivered a consistent pattern of earnings beats across recent quarters, according to company earnings reports. In the most recently reported quarter, the company posted earnings per share of $8.55 against analyst estimates of $6.85, representing a positive surprise of $1.70. The prior quarter showed an even larger beat, with actual EPS of $8.38 versus expectations of $6.01, a $2.37 upside surprise. The earliest reported quarter also exceeded consensus, delivering $7.48 per share against estimates of $6.36, a $1.12 beat. For the upcoming quarter, analyst estimates project EPS of $8.84, per consensus data. The magnitude of recent beats — averaging approximately $1.73 above estimates across three quarters — suggests that Wall Street models may continue to underestimate Eli Lilly's earnings power. The company's next earnings report is scheduled for August 6, 2026, which will serve as a key catalyst.
Wall Street Analyst Ratings for LLY
Wall Street consensus on Eli Lilly remains overwhelmingly positive, with all recent analyst actions reiterating bullish ratings, per SID consensus data. On November 2, 2026, Cantor Fitzgerald maintained its Overweight rating on LLY. On October 30, 2026, four additional firms simultaneously reaffirmed constructive positions: RBC Capital reiterated Outperform, Truist Securities maintained Buy, Wells Fargo upheld Overweight, and Morgan Stanley continued its Overweight rating, according to Wall Street analyst reports. Notably, none of the five most recent analyst updates involved a downgrade or a shift to a neutral or negative stance. The clustering of reaffirmations around the late October earnings report suggests analyst confidence was reinforced by the company's strong quarterly results. The uniform bullish alignment across major sell-side institutions — spanning both bulge-bracket banks and boutique research firms — reflects broad conviction in Eli Lilly's growth trajectory driven by its pharmaceutical pipeline and commercial execution in key therapeutic areas.
